Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 2.8.2021 | EN | Official Journal of the European Union | C 310/22 |

---

Judgment of the General Court of 16 June 2021 — Health Product Group v EUIPO — Bioline Pharmaceutical (Enterosgel)

(Case T-678/19) [(1)](#ntr1-C_2021310EN.01002201-E0001)

(EU trade mark - Invalidity proceedings - International registration designating the European Union - Figurative mark Enterosgel - No bad faith - Article 51(1)(b) of Regulation (EC) No 40/94 (now Article 59(1)(b) of Regulation (EU) 2017/1001))

(2021/C 310/26)

Language of the case: English

Parties

Applicant: Health Product Group sp. z o.o. (Warsaw, Poland) (represented by: M. Kondrat, M. Stępień and A. Przytuła, lawyers)

Defendant: European Union Intellectual Property Office (represented by: E. Markakis and V. Ruzek, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Bioline Pharmaceutical AG (Baar, Switzerland) (represented by: T. Grucelski, H. Gajek and M. Furmańska, lawyers)

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 8 August 2019 (Case R 482/2018-4), relating to invalidity proceedings between Health Product Group and Bioline Pharmaceutical.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Health Product Group sp. z o.o. to pay the costs. |

---

---

[Top](#document1)